Voya Investment Management LLC Acquires 189,081 Shares of Johnson & Johnson $JNJ

Voya Investment Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 23.8% in the third quarter, Holdings Channel.com reports. The firm owned 985,024 shares of the company’s stock after buying an additional 189,081 shares during the period. Voya Investment Management LLC’s holdings in Johnson & Johnson were worth $182,403,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Wynn Capital LLC grew its holdings in Johnson & Johnson by 0.4% during the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock worth $2,954,000 after buying an additional 57 shares in the last quarter. W.H. Cornerstone Investments Inc. lifted its stake in Johnson & Johnson by 0.7% during the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after acquiring an additional 58 shares in the last quarter. YANKCOM Partnership boosted its holdings in Johnson & Johnson by 0.8% during the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after acquiring an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.1% in the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock worth $309,000 after acquiring an additional 60 shares in the last quarter. Finally, Ellis Investment Partners LLC raised its holdings in shares of Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after purchasing an additional 62 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on JNJ shares. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a report on Monday, October 20th. Citigroup lifted their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Finally, Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a report on Wednesday. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $210.25.

Johnson & Johnson Trading Down 0.9%

NYSE:JNJ opened at $206.49 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $198.10 and its 200 day moving average is $179.19. The stock has a market capitalization of $497.49 billion, a PE ratio of 19.93, a price-to-earnings-growth ratio of 2.24 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves a subcutaneous version of Rybrevant (amivantamab) that reduces administration time from hours to minutes for EGFR‑mutated NSCLC — this materially improves patient convenience, may raise uptake vs. IV therapy and supports long‑term revenue potential for JNJ’s lung‑cancer franchise. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
• Positive Sentiment: FDA clears RYBREVANT FASPRO (amivantamab + hyaluronidase) as the first subcutaneous therapy across Rybrevant indications, enabling much shorter, simpler first‑line regimens when combined with LAZCLUZE — a regulatory win that supports commercial uptake and margins. U.S. FDA Approval of RYBREVANT FASPRO
• Positive Sentiment: JNJ’s MedTech unit won FDA clearance for the TRUFILL n‑BCA liquid embolic system to treat symptomatic chronic subdural hematoma (cSDH), expanding neurovascular indications and supporting device revenue growth. Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA
• Positive Sentiment: Media and investor sentiment is bullish: Jim Cramer highlighted JNJ’s oncology momentum and broader rotation into healthcare/defensive names, which can drive retail interest and support multiple expansion. Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
• Neutral Sentiment: Analyst/valuation commentary argues JNJ’s premium multiple is supported by accelerating growth and portfolio mix; useful context for longer‑term positioning but less likely to move near‑term price. Johnson and Johnson: Valuation Premium Justified By Accelerating Growth
• Neutral Sentiment: Macro note: rate cuts and dividend‑friendly ETF flows (e.g., mentions in MarketBeat pieces) can support demand for high‑quality dividend payers like JNJ, but impact is gradual. Rate Cuts Make These 3 Income ETFs More Attractive Than Ever
• Negative Sentiment: Near‑term pullback likely driven by profit‑taking after a large YTD move (shares are up significantly year‑to‑date); heavy volume suggests short‑term selling pressure despite positive catalysts.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.